Angiotensin Converting Enzyme I/D Polymorphism and
Cardiovascular Risk: Disclosed Story

C 2011

Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story

VAŠKŮ, Anna, Jiří BLAHÁK, Daniel BAUMGARTNER a Julie BIENERTOVÁ VAŠKŮ

Základní údaje

Originální název

Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story

Autoři

VAŠKŮ, Anna (203 Česká republika, garant, domácí), Jiří BLAHÁK (203 Česká republika, domácí), Daniel BAUMGARTNER (203 Česká republika, domácí) a Julie BIENERTOVÁ VAŠKŮ (203 Česká republika, domácí)

Vydání

1st Edition. Neuveden, Genes and Cardiovascular Function, od s. 121-134, 14 s. 2011

Nakladatel

Springer

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Odkazy

URL

Kód RIV

RIV/00216224:14110/11:00064829

Organizační jednotka

Lékařská fakulta

ISBN

978-1-4419-7206-4

DOI

http://dx.doi.org/10.1007/978-1-4419-7207-1_13

UT WoS

000294269500013

Klíčová slova anglicky

CAD; diabetes mellitus; ACE I/D

Změněno: 17. 4. 2013 15:56, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Rapid advances in molecular medicine have led to pronounced new developments in experimental and clinical cardiology. In the embrace of modern molecular biology and bridging the gap between the clinical and the genomic, cardiovascular medicine has seen major strides in the understanding of the molecular mechanisms that drive disease progression. The ability to rapidly identify candidate human genes for cardiovascular diseases lends itself to the development of diverse strategies for disease treatment and management. The wide variety of gene expressions proffers excellent targets for novel therapeutics. Gene therapy is steadily increasing in viability and represents a fascinating arena of research and clinical focus.

Návaznosti

NS10206, projekt VaV

Název: Asociace polymorfismů v genech pro metaloproteinázy, jejich inhibitory, ACE a ACE2 s centrálním pulsním tlakem u kardiovaskulárních pacientů

Investor: Ministerstvo zdravotnictví ČR, Asociace polymorfismů v genech pro metaloproteinázy, jejich inhibitory, ACE, ACE2 a apelinu s centrálním pulsním tlakem u pacientů s ischemickou chorobou srdeční

Citovat

VAŠKŮ, Anna, Jiří BLAHÁK, Daniel BAUMGARTNER a Julie BIENERTOVÁ VAŠKŮ. Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story. In Genes and Cardiovascular Function. 1st Edition. Neuveden: Springer, 2011, s. 121-134. ISBN 978-1-4419-7206-4. Dostupné z: https://dx.doi.org/10.1007/978-1-4419-7207-1_13.

@inbook{963599,
   author = {Vašků, Anna and Blahák, Jiří and Baumgartner, Daniel and Bienertová Vašků, Julie},
   address = {Neuveden},
   booktitle = {Genes and Cardiovascular Function},
   doi = {http://dx.doi.org/10.1007/978-1-4419-7207-1_13},
   edition = {1st Edition},
   keywords = {CAD; diabetes mellitus; ACE I/D},
   howpublished = {tištěná verze "print"},
   language = {eng},
   location = {Neuveden},
   isbn = {978-1-4419-7206-4},
   pages = {121-134},
   publisher = {Springer},
   title = {Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story},
   url = {http://www.springerlink.com/content/978-1-4419-7206-4/#section=930283&page=1},
   year = {2011}
}

TY  - CHAP
ID  - 963599
AU  - Vašků, Anna - Blahák, Jiří - Baumgartner, Daniel - Bienertová Vašků, Julie
PY  - 2011
TI  - Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story
VL  - Neuveden
PB  - Springer
CY  - Neuveden
SN  - 9781441972064
KW  - CAD
KW  - diabetes mellitus
KW  - ACE I/D
UR  - http://www.springerlink.com/content/978-1-4419-7206-4/#section=930283&page=1
N2  - Rapid advances in molecular medicine have led to pronounced new developments in experimental and clinical cardiology. In the embrace of modern molecular biology and bridging the gap between the clinical and the genomic, cardiovascular medicine has seen major strides in the understanding of the molecular mechanisms that drive disease progression. The ability to rapidly identify candidate human genes for cardiovascular diseases lends itself to the development of diverse strategies for disease treatment and management. The wide variety of gene expressions proffers excellent targets for novel therapeutics. Gene therapy is steadily increasing in viability and represents a fascinating arena of research and clinical focus.
ER  -

VAŠKŮ, Anna, Jiří BLAHÁK, Daniel BAUMGARTNER a Julie BIENERTOVÁ VAŠKŮ. Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story. In \textit{Genes and Cardiovascular Function}. 1st Edition. Neuveden: Springer, 2011, s.~121-134. ISBN~978-1-4419-7206-4. Dostupné z: https://dx.doi.org/10.1007/978-1-4419-7207-1\_{}13.

Podrobný výpis o publikaci